pdf   xlsx method abbreviations

refractory classic Hodgkin lymphoma (R/R cHL), pembrolizumab alone , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

progression or deaths (PFS) 0.65 [0.48, 0.88]< 10%1 study (1/-)99.7 %NAnot evaluable important-
objective responses (ORR) 1.68 [1.05, 2.68]> 10%1 study (1/-)98.5 %NAnot evaluable non important-

safety endpoints 00

AE leading to death (grade 5) 1.55 [0.26, 9.42]< 10%1 study (1/-)31.7 %NAnot evaluable non important-
TRAE (any grade) 0.87 [0.51, 1.47]< 10%1 study (1/-)70.3 %NAnot evaluable non important-
TRAE (grade 3-4) 0.70 [0.40, 1.21]< 10%1 study (1/-)89.7 %NAnot evaluable non important-
TRAE leading to death (grade 5) 2.06 [0.07, 61.91]< 10%1 study (1/-)34.1 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 0.75 [0.39, 1.43]< 10%1 study (1/-)81.1 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Abdominal pain TRAE (grade 3-4) 2.06 [0.07, 61.91]< 10%1 study (1/-)34.1 %NAnot evaluable non important-
Acute kidney injury TRAE (grade 3-4) 4.15 [0.19, 92.82]< 10%1 study (1/-)18.8 %NAnot evaluable non important-
Anaemia TRAE (grade 3-4) 1.03 [0.06, 16.58]< 10%1 study (1/-)49.3 %NAnot evaluable non important-
Colitis TRAE (grade 3-4) 0.51 [0.02, 15.37]< 10%1 study (1/-)64.8 %NAnot evaluable non important-
Constipation TRAE (grade 3-4) 1.03 [0.02, 52.11]< 10%1 study (1/-)49.5 %NAnot evaluable non important-
Diarrhoea TRAE (grade 3-4) 4.15 [0.19, 92.82]< 10%1 study (1/-)18.8 %NAnot evaluable non important-
Eczema TRAE (grade 3-4) 0.51 [0.02, 15.37]< 10%1 study (1/-)64.8 %NAnot evaluable non important-
Fatigue TRAE (grade 3-4) 1.03 [0.02, 52.11]< 10%1 study (1/-)49.5 %NAnot evaluable non important-
Febrile neutropenia TRAE (grade 3-4) 0.51 [0.02, 15.37]< 10%1 study (1/-)64.8 %NAnot evaluable non important-
Hyperthyroidism TRAE (grade 3-4) 1.03 [0.02, 52.11]< 10%1 study (1/-)49.5 %NAnot evaluable non important-
Hypothyroidism TRAE (grade 3-4) 1.03 [0.02, 52.11]< 10%1 study (1/-)49.5 %NAnot evaluable non important-
Increase AST TRAE (grade 3-4) 0.51 [0.02, 15.37]< 10%1 study (1/-)64.8 %NAnot evaluable non important-
Increased ALT TRAE (grade 3-4) 0.51 [0.02, 15.37]< 10%1 study (1/-)64.8 %NAnot evaluable non important-
Infusion-related reactions TRAE (grade 3-4) 0.17 [0.01, 3.39]< 10%1 study (1/-)87.5 %NAnot evaluable non important-
Leucopenia TRAE (grade 3-4) 0.17 [0.01, 3.39]< 10%1 study (1/-)87.5 %NAnot evaluable non important-
Myocarditis TRAE (grade 3-4) 2.06 [0.07, 61.91]< 10%1 study (1/-)34.1 %NAnot evaluable non important-
Nausea TRAE (grade 3-4) 1.03 [0.02, 52.11]< 10%1 study (1/-)49.5 %NAnot evaluable non important-
Nephritis TRAE (grade 3-4) 2.06 [0.07, 61.91]< 10%1 study (1/-)34.1 %NAnot evaluable non important-
Neutropenia TRAE (grade 3-4) 0.27 [0.07, 0.97]< 10%1 study (1/-)97.7 %NAnot evaluable non important-
Paraesthesia TRAE (grade 3-4) 0.25 [0.01, 5.69]< 10%1 study (1/-)80.3 %NAnot evaluable non important-
Pneumonia TRAE (grade 3-4) 1.03 [0.14, 7.39]< 10%1 study (1/-)48.9 %NAnot evaluable non important-
Pneumonitis TRAE (grade 3-4) 6.38 [0.76, 53.66]< 10%1 study (1/-)4.5 %NAnot evaluable non important-
Pruritus TRAE (grade 3-4) 1.03 [0.02, 52.11]< 10%1 study (1/-)49.5 %NAnot evaluable non important-
Pyrexia TRAE (grade 3-4) 2.06 [0.07, 61.91]< 10%1 study (1/-)34.1 %NAnot evaluable non important-
Rash TRAE (grade 3-4) 1.03 [0.02, 52.11]< 10%1 study (1/-)49.5 %NAnot evaluable non important-
Thrombocytopenia TRAE (grade 3-4) 4.15 [0.19, 92.82]< 10%1 study (1/-)18.8 %NAnot evaluable non important-
Urticaria TRAE (grade 3-4) 2.06 [0.07, 61.91]< 10%1 study (1/-)34.1 %NAnot evaluable non important-
Vomiting TRAE (grade 3-4) 2.06 [0.07, 61.91]< 10%1 study (1/-)34.1 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons